Literature DB >> 20715493

[Methylphenidate: pharmacology, indication and potential of abuse].

Hirokuni Tagaya1.   

Abstract

Methylphenidate enhances dopaminergic neurotransmission in the central nervous system by same manner with cocaine and amphetamine that bind to the dopamine transporter and inhibit dopamine uptake. Methylphenidate improves social functions as well as clinical symptoms of patients suffered of narcolepsy and attention deficit hyperactivity disorder (ADHD), though it has the potential of abuse. It is reported that approximately 4% of older teens and emerging adults in the US annually misusing methylphenidate. Non-medical/illegal use of methylphenidate causes many consequences including addiction, negative reactions and medical complications. Growing number of illegal trades of methylphenidate and medical complications caused by misuse of methylphenidate urged Japanese government to introduce regulations limiting access to prescribed methylphenidate in 2008.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715493

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  6 in total

1.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 2.  Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review.

Authors:  Javier Quintero; José R Gutiérrez-Casares; Cecilio Álamo
Journal:  Neurol Ther       Date:  2022-08-11

3.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

4.  Reduction of Methylphenidate Induced Anxiety, Depression and Cognition Impairment by Various doses of Venlafaxine in Rat.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Andia Ebrahimzadeh; Setare Farokhi Larijani; Zohreh Khajehamedi
Journal:  Int J Prev Med       Date:  2015-06-04

5.  Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center.

Authors:  Zahra Khajehpiri; Javad Mahmoudi-Gharaei; Toktam Faghihi; Iman Karimzadeh; Hossein Khalili; Mostafa Mohammadi
Journal:  J Res Pharm Pract       Date:  2014-10

6.  Influence of methylphenidate treatment assumptions on cognitive function in healthy young adults in a double-blind, placebo-controlled trial.

Authors:  Jean-Luc Mommaerts; Gerlinde Beerens; Lieve Van den Block; Eric Soetens; Sandrina Schol; Erwin Van De Vijver; Dirk Devroey
Journal:  Psychol Res Behav Manag       Date:  2013-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.